In the Thick of It podcast

A Breakthrough for Non-Obstructive HCM: Inside the ACACIA Trial

0:00
21:45
Manda indietro di 15 secondi
Manda avanti di 15 secondi

Dr. Martin Maron, director of the HCM Center at Lahey Hospital & Medical Center and national principal investigator of the ACACIA-HCM trial, joins Dr. Florian Rader of the HCM Center at Cedars-Sinai to discuss the trial’s findings on aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy (HCM). The conversation covers the long-standing treatment gap for the roughly half of non-obstructive patients who remain symptomatic on beta blockers or calcium channel blockers, the phase 3 trial design, and its co-primary endpoints of health status (KCCQ) and exercise capacity (peak VO2). Dr. Maron explains why the results are clinically meaningful and reviews secondary outcomes, including improvements in NT-proBNP and measures of diastolic function, along with consistent benefit across pre-specified subgroups such as patients with mid-cavitary obstruction. Additionally, the two discuss safety findings on ejection fraction reductions and heart failure events during dose titration, and how real-world monitoring and titration may look if aficamten is approved for this indication.  

Altri episodi di "In the Thick of It"